Anti-Coagulants - Ukraine

Ukraine

Highlights

The Anti-Coagulants market in Ukraine is expected to witness a significant increase in revenue, with projections indicating that it will reach US$17.59m in the year 2024.
Furthermore, this market is anticipated to display a steady annual growth rate (CAGR 2024-2029) of 7.72%, resulting in a market volume of US$25.51m by the end of 2029.
When compared on a global scale, it is important to note that United States is projected to generate the highest revenue in this market, with an estimated amount of US$16.74bn in the year 2024.
The demand for anti-coagulants in Ukraine has been steadily increasing due to the aging population and rising prevalence of cardiovascular diseases.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The demand for Anti-Coagulants in Ukraine has been steadily increasing over the past few years.

Customer preferences: Anti-Coagulants are used to prevent blood clots, which can lead to serious health problems such as stroke and heart attack. In Ukraine, the aging population and the high prevalence of cardiovascular diseases have contributed to the growing demand for Anti-Coagulants. Additionally, the increasing awareness of the importance of preventive healthcare has also led to more people seeking treatment for their conditions.

Trends in the market: The Anti-Coagulants market in Ukraine is dominated by oral anticoagulants, which are more convenient and easier to use compared to traditional injectable anticoagulants. The market is also seeing a shift towards newer oral anticoagulants, such as direct oral anticoagulants (DOACs), which have fewer side effects and do not require regular blood tests. However, the high cost of DOACs remains a barrier for many patients.

Local special circumstances: The political and economic instability in Ukraine has had an impact on the healthcare sector, including the availability and affordability of Anti-Coagulants. The conflict in eastern Ukraine has disrupted supply chains and led to shortages of certain medicines, including Anti-Coagulants. Additionally, the devaluation of the Ukrainian currency has made imported medicines more expensive, further limiting access to treatment for some patients.

Underlying macroeconomic factors: The healthcare sector in Ukraine is underfunded, with limited resources for research and development. This has led to a reliance on imported medicines, which are often more expensive than locally produced alternatives. The government has implemented measures to promote the local production of medicines, including Anti-Coagulants, but progress has been slow. The ongoing political and economic instability in Ukraine also poses challenges for the healthcare sector, including the availability and affordability of medicines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.